In this regard, we used the validated anti-EGFR CL4 nuclease-resistant RNA-aptamer, generated in our laboratory, which was previously found to inhibit the derived tumor growth of NSCLC [33], glioblastoma [34,35], and triple-negative breast cancer (TNBC) [36,37]. This evidence concerns the gene EGFR and neoplasm.